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Interleukin 10 reversed delayed gastric emptying in diabetic
mice. It increased heme oxygenase 1 expression and
normalized electrical activity and networks of interstitial
cells of Cajal in the stomach. Thus, interleukin 10 is a
potential therapy for diabetic gastroparesis.
BACKGROUND & AIMS: Gastroparesis is a complication of
diabetes characterized by delayed emptying of stomach con-
tents and accompanied by early satiety, nausea, vomiting, and
pain. No safe and reliable treatments are available. Interleukin
10 (IL10) activates the M2 cytoprotective phenotype of mac-
rophages and induces expression of heme oxygenase 1 (HO1)
protein. We investigated whether IL10 administration could
improve gastric emptying and reverse the associated cellular
and electrical abnormalities in diabetic mice.
METHODS: Nonobese diabetic mice with delayed gastric
emptying were given either IL10 (0.1–1 mg, twice/day) or
vehicle (controls). Stomach tissues were isolated, and sharp
microelectrode recordings were made of the electrical activity
in the gastric muscle layers. Changes to interstitial cells of Cajal
(ICC), reduced nicotinamide adenine dinucleotide phosphate
diaphorase, and levels and distribution of HO1 protein were
determined by histochemical and imaging analyses of the same
tissues.
RESULTS: Gastric emptying remained delayed in vehicle-
treated diabetic mice but returned to normal in mice given
IL10 (n ¼ 10 mice; P < .05). In mice given IL10, normalization
of gastric emptying was associated with a membrane potential
difference between the proximal and distal stomach, and lower
irregularity and higher frequency of slow-wave activity,
particularly in the distal stomach. Levels of HO1 protein were
higher in stomach tissues from mice given IL10, and ICC net-
works were more organized, better connected, and more evenly
distributed compared with controls.
CONCLUSIONS: IL10 increases gastric emptying in diabetic
mice and has therapeutic potential for patients with diabetic
gastroparesis. This response is associated with up-regulation of
HO1 and repair of connectivity of ICC networks. (Cell Mol
Gastroenterol Hepatol 2016;2:454–467; http://dx.doi.org/
10.1016/j.jcmgh.2016.04.006)Keywords: Alternatively Activated Macrophages; Heme
Oxygenase 1; Electrical Slow Wave.
astroparesis is a complication of diabetes deﬁned byGdelayed gastric emptying without obstruction that is
accompanied by early satiety, nausea, vomiting, and pain.1–3
No safe and reliable treatments are available.4 Identiﬁcation
of the cellular changes associated with gastroparesis in
human beings5,6 and in mouse models of gastroparesis7,8
have identiﬁed possible therapeutic targets. The nonobese
diabetic (NOD) mouse in particular has proved to be a
useful model of human diabetic gastroparesis.7,9–11
In previous studies using a noninvasive gastric emptying
test, a proportion of diabetic NOD mice developed delayed
emptying of solids while the remainder remained resistant
to this complication.11 Although most animals show loss of
neuronal nitric oxide synthase upon the development of
diabetes, the development of delayed gastric emptying was
concurrent with reduced expression of the receptor tyrosine
kinase, Kit, a marker for interstitial cells of Cajal (ICC).7 This
is consistent with studies showing impairment to ICC net-
works and loss of neuronal nitric oxide synthase in mice
with long-standing diabetes.9,10 Subsequent studies deter-
mined that animals resistant to the development of delayed
emptying maintained high expression of heme oxygenase-1
(HO1) in alternatively activated M2-macrophages in stom-
ach muscle layers.7,8 In studies of the human gastric body, a
correlation between the numbers of ICC and CD206-positive
M2-macrophages was found.12
These studies have suggested that targeting HO1 may
ameliorate diabetic gastroparesis. Indeed, treatment of
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HO1 normalized gastric emptying and Kit expression
levels.7,8 These therapies were accompanied by increased
numbers of HO1-positive, M2-macrophages in gastric mus-
cularis propria.8 Hemin (as Panhematin, Ovation Pharma-
ceuticals, Deerﬁeld, IL) also up-regulates HO1 expression in
human beings, although administration of hemin must be
performed under close supervision.13 These data suggest
that HO1 is a promising therapeutic target for diabetic gas-
troparesis,14 but treatment with hemin has signiﬁcant dis-
advantages including the delivery method and side effects.
Consequently, a need exists to determine other modal-
ities to target HO1. In the present study we tested inter-
leukin 10 (IL10) as a treatment for delayed gastric emptying
in NOD mice. The rationale was that IL10 expression is up-
regulated during treatment by carbon monoxide (CO) of
postoperative ileus in mice15 and that IL10 had an obliga-
tory role in postoperative intestinal recovery.16 IL10 up-
regulates HO1 expression17 and is expressed at high levels
in M2-macrophages. IL10 increases the numbers of M2-
macrophages18 directly and suppresses expression of M1-
macrophages.19 In addition, in diabetic mice with delayed
emptying, IL10 messenger RNA levels were decreased.8
In previous studies on diabetic mice and rats, ICC net-
works and the electrical slow-wave activity that originates
from ICC were absent or abnormal, especially in the distal
antrum.9,20 In human beings, electrical dysrhythmias also
were reported in diabetic gastroparesis.21–23 However,
electrical properties and immunohistochemical differences
were not comparatively studied in rodents with delayed
gastric emptying or after normalization of gastric emptying.
Thus, for the current study we made electrical recordings
from multiple locations in the stomach of treated mice and
subsequently immunolabeled for HO1 and Kit. Therefore,
we were able to examine associations between gastric
emptying of the mice and physiological and anatomic
changes to the stomach, and the response of those changes
to treatment with IL10.Materials and Methods
Animals and Experimental Design
Animal procedures were performed using protocols
approved by the Mayo Clinic’s Institutional Animal Care and
Use Committee. Female NOD/ShiLtJ mice were used as
previously described.7,8,11 Blood glucose levels were
measured every week until the onset of diabetes, after
which point they were measured daily. Single drops of blood
were collected from the vascular bundle located at the rear
of the jaw bone of the mice. The amount of blood collected
was monitored carefully to avoid anemia. Mice were
considered diabetic when the glucose levels were higher
than 250 mg/dL. The incidence of diabetes was 57% in this
study. Subtherapeutic insulin (Lantus insulin glargine;
Sanoﬁ-Aventis US LLC, Bridgewater, NJ) was injected once
daily intraperitoneally when the glucose levels were higher
than 500 mg/dL to keep the diabetic mice alive, yet also
keep the blood glucose levels between 400 and 600 mg/dL
to allow complications of diabetes to develop. To determinethe levels of oxidative stress in the diabetic mice, the con-
centration of malondialdehyde (MDA) was measured in
blood plasma. The concentration of thiobarbituric acid–
reactive substances was calculated as malondialdehyde
equivalents using a commercial kit (Oxi-Tek; Zeptometrix
Corp, Buffalo, NY). Five microliters of plasma sample was
mixed with an equal volume of sodium dodecyl sulfate so-
lution and 125 mL of 5% thiobarbituric acid/acetic acid
reagent. Samples were incubated for 60 minutes at 95C.
After centrifugation at 1600g, the absorbances of superna-
tants from samples were read at 532 nm using a spectro-
photometer (NanoDrop Technology, Wilmington, DE).
Gastric emptying of solids was measured using a
13[C]-octanoic acid breath test.11 Three baseline values of
times to half maximal emptying (T1/2) for gastric emptying
were obtained before the development of diabetes. After the
onset of diabetes, gastric emptying was measured weekly.
After the development of delayed gastric emptying, mice
were assigned to treatment with vehicle or IL10 (1 or 0.1 mg
intraperitoneally, twice a day; GenScript, Piscataway, NJ; or
Insight Genomics, Falls Church, VA). We alternated the
assignment to treatment based on the development of
delayed gastric emptying only and without regard to any
metabolic parameters such as blood glucose or MDA levels.
Treatment began after 2 consecutive measurements of
delayed gastric emptying and continued as 2 doses every
day until 2 consecutive normal values for T1/2 were ob-
tained or a maximum of 10 weeks after the start of treat-
ment. The duration and frequency of vehicle treatment was
matched to the length of IL10 treatment. All mice with
delayed gastric emptying also had MDA levels that were
signiﬁcantly greater than the upper limit of the normal
range for MDA in diabetic NOD mice (>73 nmol/mL).7 At
the completion of the study, mice were killed by carbon
dioxide exposure followed by cervical dislocation. Whole
stomachs were cut along the lesser curvature and the mu-
cosa was removed. Electrical recordings and immunohisto-
chemical studies then were performed on the tissues. The
experimental protocol is outlined in Figure 1A.Electrophysiological Recordings
From the Gastric Smooth Muscle
Smooth muscle membrane potential and electrical slow
waves were recorded from the circular muscle of every
tissue from the treated mice at 12 deﬁned regions distrib-
uted from the proximal body to distal antrum (Figure 1B).
Sharp glass microelectrodes ﬁlled with 3 mol/L KCl (input
resistances, 40–70 MU) were used to record membrane
potential and electrical slow wave. The locations of the
recording sites were documented on a digital image, after
which the tissue was ﬁxed in the recording dish (Figure 1B).
Electrical slow-wave events were analyzed using Clampﬁt
(Molecular Devices, LLC, Sunnyvale, CA). An analysis was
performed on recordings longer than 2 minutes in duration
in which at least 12 slow-wave events were observed as
follows. Slow-wave events from stable recordings were
identiﬁed using the “template search” event discriminator
function in Clampﬁt. For each trace, a template was derived
Figure 1. (A) Experimental design. Gastric emptying (GE) is indicated by larger arrows, treatment is indicated by small arrows.
(B) Location of electrical recording and image collection sites.
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ﬁt using the established template, and each event was
conﬁrmed by the user for goodness-of-ﬁt. Automated ﬁtting
allowed quantiﬁcation of the baseline membrane potential,
peak amplitude, and interevent interval. The interevent in-
terval represents the frequency of the pacemaking depo-
larization. Averages and variances were obtained for each
recording from each area.
Immunohistochemistry
After completion of the electrical recordings, the intact
tissues from each mouse were ﬁxed in acetone and doubly
labeled for Kit and HO1. Antibodies used were a rabbit
polyclonal anti-HO1 antibody (Stressgen Biotech Corp, Vic-
toria, BC, Canada) and rat monoclonal anti-Kit antibody
(ACK2; eBioscience, San Diego, CA). The tissue was washed 3
times in 0.1 mol/L phosphate-buffered saline (PBS), and then
blocked in 10% normal donkey serum (NDS) in PBS and
0.3% Triton overnight at 4C. The Kit antibody (ﬁnal con-
centration, 1.7 mg/mL) was applied by incubation in 5%
NDS/PBS/0.3% Triton X-100 (Thermo Fisher, Waltham MA)
for 2 days at 4C. After the tissue was ﬁxed again in 4%
paraformaldehyde in 0.1 mol/L phosphate buffer and washed
3 times in PBS, anti-HO1 antibody (ﬁnal concentration, 0.125
mg/mL; Stressgen Biotech Corp) in 5% NDS/PBS/0.3%
Triton was applied overnight at 4C. After rinsing in PBS,
donkey anti-rabbit ﬂuorescein isothiocyanate (ﬁnal concen-
tration, 3 mg/mL; Chemicon, Temecula, CA) and donkey anti-
rat Cy3 (ﬁnal concentration, 3 mg/mL; Chemicon) were
added in 2.5% NDS/PBS/0.3% Triton and incubated over-
night at 4C in the dark. After rinsing in PBS, nuclei in the
tissue were stained by incubating the tissue for 30 minutes at
4C with 0.3 mmol/L 4’,6-diamidino-2-phenylindole dihy-
drochloride (Molecular Probes, Inc, Eugene, OR) in water.
To identify the HO1-positive cells that had macrophage-
like morphology in the muscularis propria of diabetic mice
treated with IL10, we treated 2 diabetic mice with 1 mg IL10
twice daily for 1 week. These mice were B6;C3Fe wild-type
mice that were made diabetic by treatment with 160 mg/kg
streptozotocin as described previously.24 Treatment withIL10 was started after 10 weeks of diabetes. The mice had
normal gastric emptying. After killing the mice, we immuno-
labeled the gastric muscularis propria as a whole-mount
preparation with the pan-macrophage marker F4/80, the
M2 macrophage marker CD206, and HO1 as previously re-
ported.8 Brieﬂy, tissues were incubated in F4/80 rat anti-
mouse antibody (0.4 mg/mL; Thermo Fisher, Waltham, MA)
in Ca2þ-containing, HEPES-buffered physiologic salt solution
(135 mmol/L NaCl, 5 mmol/L KCl, 2 mmol/L CaCl2,
1.2 mmol/L MgCl2, 10 mmol/L glucose, and 10 mmol/L
HEPES, adjusted to pH 7.4 with Tris) at 37C for 90 minutes in
the dark. The tissue then was ﬁxed in 4% paraformaldehyde
in 0.1 mol/L phosphate buffer. After blocking in 10% NDS,
0.1 mol/L PBS, 0.3% Triton overnight at 4C, rabbit anti-HO1
(0.125 mg/mL) and goat anti-CD206 (0.5 mg/mL; Santa Cruz
Biotech, Santa Cruz, CA) antibodies were applied by incuba-
tion in 5% NDS/1 PBS/0.3% Triton overnight at 4C. After
rinsing in PBS, donkey anti-rabbit cy3 (0.5 mg/mL; Jackson
ImmunoResearch, West Grove, PA) and donkey anti-goat
cy5 (0.5 mg/mL; Jackson ImmunoResearch), both in 2.5%
NDS/1 PBS/0.3% Triton were added overnight at 4C in the
dark. The tissues then were washed in PBS and water and the
nuclei in the tissue were stained by incubating for 30 minutes
at 4C with 0.3 mmol/L 4’,6-diamidino-2-phenylindole dihy-
drochloride in water and mounted for viewing.
Assessment of Nitric Oxide Synthase
Expression in Myenteric Neurons
Nitric oxide synthase expression was determined by
reduced nicotinamide adenine dinucleotide phosphate
(NADPH) diaphorase histochemistry as previously re-
ported.25 Tissues, ﬁxed in acetone and paraformaldehyde,
were washed 5 times over 30 minutes in 1 PBS and then
pinned on Sylgard, Dow Corning, Midland MI in a small Petri
dish. Tissues then were washed 2 times in 100 mmol/L
TrisCl for 5 minutes and permeabilized in 100 mmol/L
TrisCl/0.3% Triton X-100. The labeling solution contained
0.2 mg/mL nitroblue tetrazolium and 1 mg/mL NADPH
dissolved in 100 mmol/L TrisCl/0.3% Triton X-100 and was
incubated with the tissue at 37C until the reaction was
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mmol/L TrisCl/0.3% Triton X-100. Tissues then were
mounted for examination at 20 magniﬁcation on an up-
right microscope and counting of positively labeled cells.
Assessment and Quantiﬁcation of Kit and
HO1 Immunoreactivity
Tissues were examinedwith a confocal microscope using a
20 (numerical aperture, 0.95) XLUMPlanFl objective
(Olympus, Tokyo, Japan) in Fluoview (Olympus) at a resolu-
tion of 0.994 0.994 1.13 mm (X Y Z). Stacks of images
across the full thickness of themuscleswere collected from the
documented electrical recording sites. To assess labeling
across the whole stomach, tissues were examined with an
Olympus IX70 microscope by 2 investigators blind to the
tissue source. For quantiﬁcation of the labeling speciﬁcally at
the electrical recording sites, all of the confocal image stacks
(120 images for each immunolabel) were ﬂattened into pro-
jections using the FV10-ASW Viewer (Olympus), assigned a
randomnumber, and uploaded onto a digital album in random
order. The images then were assessed using the same
parameters as used for the whole tissue by 2 investigators
blind to the tissue source. The images were scored on a 10-cm
visual analogue scale for network density, connectivity, and
structural preservation. The scores for each image then were
averaged and the code was broken to ﬁnd which image
belonged to which ﬁeld and animal.
Quantiﬁcation of Connectivity in the Confocal
Images of Kit Immunoreactivity
The absolute volumes of Kit-positive immunoreactivity in
4 ﬁelds from 2 areas in each tissue where electrical abnor-
malities were most evident in the vehicle-treated mice were
obtained by volume rendering and 3-dimensional recon-
struction from confocal image stacks of ICC across the full
thickness of the muscle using Analyze (Mayo Foundation,
Rochester, MN) as previously described.26 The reconstructed
Kit-positive 3-dimensional structures from each ﬁeld were
subjected to a morphologic 3  3  3 opening operation.
This deleted any region of the structures that did not contain
a 3  3  3 voxel (12.86 mm3) cube, thereby breaking up
larger tenuously connected structures into 2 or more smaller
structures. After opening, the remaining connected struc-
tures larger than 100 voxels (143 mm3) were counted. A
larger number of such structures within similar total vol-
umes indicated reduced connectivity of the total volume.
Statistics were performed with Prism (GraphPad, La
Jolla, CA) using the appropriate tests as described in the
Results section. All authors had access to the study data and
have reviewed and approved the ﬁnal manuscript.
Results
Blood Glucose and Oxidative Stress
Levels in Diabetic Mice
Mice used for this study developed diabetes at 19.6 ± 1.6
weeks (mean ± SEM, n ¼ 10 mice), and remained diabetic
throughout the study. Thirty percent of diabetic micedeveloped delayed gastric emptying at a mean of 5.4 ± 0.5
weeks (mean ± SEM, n ¼ 10 mice) after the onset of dia-
betes. This is consistent with previous reports.7 Animals
with delayed gastric emptying were enrolled consecutively
until 10 mice completed the study. Five mice received
vehicle and 5 mice received IL10. There were no signiﬁcant
differences in blood glucose levels for the mice whether
treated with vehicle or IL10 at any point during the pro-
gression of the study and diabetic mice with delayed gastric
emptying did not have signiﬁcantly different blood glucose
levels compared with diabetic mice with normal gastric
emptying (Figure 2A). Vehicle and IL10-treated mice
received similar amounts of insulin during the study (3.4 ±
1.80 IU/day vs 2.6 ± 0.98 IU/day, respectively, mean ± SEM;
n ¼ 5 mice; P ¼ .67, t test).
Systemic oxidative stress was measured using plasma
MDA levels. Nondiabeticmice had low levels ofMDA (6.0± 0.6
and 6.0 ± 0.5 nmol/mL for mice assigned to vehicle and IL10,
respectively, mean ± SEM; n ¼ 5 in each group) (Figure 2B).
After the development of diabetes but while gastric emptying
remained normal, MDA levels were not signiﬁcantly different
between themice assigned to the 2 treatments (41± 16.3 and
30 ± 3.7 nmol/mL for mice assigned to vehicle and IL10,
respectively, mean± SEM; n¼ 5 in each group) (Figure 2B). At
the onset of delayed gastric emptying, MDA levels were
increased further above the previously established normal
range for diabetic NOD mice with normal gastric emptying
(normal mean, 53.05; range, 28–73 nmol/mL; n ¼ 19 mice),7
in both groups of mice (129 ± 28.9 and 226 ± 16.8 nmol/mL,
mean ± SEM, vehicle and IL10, respectively). These levels at
the onset of delayed gastric emptying were higher than the 73
nmol/mL threshold previously found to be associated with
delayed gastric emptying in diabetic NOD mice.7 In mice
treatedwith IL10,MDA levels decreased to the levels (56±9.9
nmol/mL, mean ± SEM) typical for diabetic NOD mice with
normal gastric emptying whereas MDA levels in the vehicle-
treated mice remained greater than the upper limit of this
range (Figure 2B) (221± 37.2 nmol/mL, mean± SEM). These
values were higher than those before the development of
delayed gastric emptying and higher than the levels in mice
treated with IL10 (Figure 2B).Gastric Emptying in Diabetic Mice
After IL10 Treatment
Gastric emptying values are shown in Figure 2C. Before
the development of diabetes, gastric emptying values were
in the normal range.11 T1/2 values were 97 ± 7.1 and 98 ±
6.0 minutes for mice assigned to vehicle and IL10, respec-
tively (mean ± SEM; n ¼ 5 in each group) (Figure 2C). The
gastric emptying values in diabetic mice after development
of a delay were not different between groups (T1/2 ¼ 174 ±
13.9 min for vehicle, 183 ± 19.4 min for IL10, mean ± SEM;
n ¼ 5) (Figure 2C). In mice that were treated with IL10,
gastric emptying returned to normal in all animals after 8.8
± 1.9 weeks (T1/2 ¼ 106 ± 3.4 min, mean ± SEM; n ¼ 5)
(Figure 2C), whereas mice treated for the same period
with vehicle continued to have delayed gastric emptying
(T1/2 ¼ 159 ± 9.5 min, mean ± SEM; n ¼ 5) (Figure 2C).
Figure 2. Effects of IL10 treatment. (A) Glucose levels (bars, medians with interquartile range; whiskers, 5th/95th percentiles).
*Higher glucose levels for diabetic vs nondiabetic mice (n ¼ 5; 2-way analysis of variance with Bonferroni post-test). (B)
Malondialdehyde levels were associated signiﬁcantly with delayed gastric emptying and response to IL10 treatment but not
diabetes. Circles, values for each mouse; whiskers, means ± SE; dotted lines, 5th/95th percentile of MDA levels in diabetic
NOD mice with normal gastric emptying. (C) Gastric emptying. Circles, data of each mouse; whiskers, means ± SE; dotted
lines, 5th/95th percentile of T1/2 values in nondiabetic mice. *P < .05 (n ¼ 5; 1-way analysis of variance with the Tukey post-
test). Db, diabetic; GE, gastric emptying.
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delayed gastric emptying over an 8-week period with no
effects on blood glucose levels. We next determined the
effect of IL10 on electrical activity.Electrical Activity After Treatment With IL10
Stable electrical recordings were made from 12 areas in
the corpus and antrum of all diabetic mice with delayed
gastric emptying that then completed the study of the ef-
fects of treatment with vehicle or IL10 on gastric emptying
(120 regions in total). In regions where slow waves could be
detected (116 areas), there were differences in the prop-
erties of the electrical activity between vehicle- and IL10-
treated mice. Quiescent areas were all in the proximal
body (areas 1–3), close to the fundus, an area where slow
waves usually are not detected. The quiescent areas were
found in 2 tissues from both vehicle- and IL10-treated mice.Peak amplitudes of the slow waves recorded in the distal
region (areas 10–12) of the IL10-treated mice did not vary
as much as the peak amplitudes of slow waves in the same
regions from vehicle-treated mice. In the more proximal
regions of the stomach, irregularities in the slow waves from
3 of 5 vehicle-treated animals also were observed, but this
was not observed for any IL10-treated mice. In all tissues
from vehicle-treated mice, an irregular slow-wave pattern
was recorded in the distal antrum (Figure 3A), whereas the
slow-wave activity for the IL10-treated animals did not
show these irregularities in the equivalent areas of the distal
antrum (Figure 3B). This reduction in the variability of the
slow wave in the antrum after IL10 treatment was
conﬁrmed by quantifying the peak amplitude of the slow
waves. We averaged the amplitudes of all events in each
recording, both low- and high-amplitude events, but found
that there was no difference in the actual amplitude of the
slow waves by comparing either individual regions or
Figure 3. Electrical activ-
ity. Slow-wave activity in
the distal antrum of all
(A) vehicle-treated and (B)
IL10-treated mice. Note the
variations in peak ampli-
tude of the slow waves in
the vehicle-treated mice
that are absent in the IL10-
treated mice.
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signiﬁcantly more variation in the amplitude for the most
distal regions (Figure 4A) (P < .05, unpaired t test; n ¼ 5).
The events recorded from IL10-treated mice also had
signiﬁcantly higher frequencies (4.05 ± 0.34 cycles/min)
with, on average, a 22% shorter peak-to-peak interevent
interval compared with vehicle-treated mice (3.18 ± 0.4
cycles/min; P ¼ .0052, unpaired t test; n ¼ 5) (Figure 4B). A
faster frequency also was detected in tissues from IL10-
treated mice by comparing the interevent intervals at
every individual recording location (P < .05, Wilcoxon
matched-pairs test). A smooth muscle membrane potential
gradient exists between the proximal and distal stomach in
dogs.27 In healthy wild-type mice, the smooth muscle
membrane potential in the antrum is reported to be
hyperpolarized relative to the fundus,28 and the values are
similar to those found in the equivalent areas of the canine
stomach.27 The membrane potential difference between the
proximal and distal areas of the stomach was not signiﬁcant
in tissues from the diabetic with delayed emptying, vehicle-
treated mice (corpus 1–3, Membrane potential, (Em) ¼ -54.2
± 1.76 vs antrum 7–9, antrum, -60.6 ± 2.87 mV, NS, n ¼ 5),
although there was a signiﬁcant membrane potential dif-
ference in tissues from IL10-treated mice, with proximal
regions (areas 1–3, corpus, Em ¼ -51.0 ± 0.96 mV, mean ±
SEM) signiﬁcantly more depolarized than distal regions
(areas 7–9, antrum, Em ¼ -64.7 ± 3.00 mV, mean ± SEM; P <
.01, 2-way analysis of variance with Bonferroni post-test;
n ¼ 5) (Figure 4C). In addition, the variation in the mem-
brane potential values across the whole tissue was signiﬁ-
cantly greater in the IL10-treated mice compared with the
vehicle-treated mice (Figure 4D) (P ¼ .03, F-test).Changes in Kit-Positive ICC, HO1-Positive
Cells, and Neuronal Nitric Oxide Synthase
Activity After IL10 Treatment
We next determined if the IL10-induced changes
in gastric emptying and electrical activity were accompanied
by cellular changes. All of the tissues used forelectrophysiology were processed as whole mounts and
immunolabeled using antibodies to HO1 and Kit. The whole
tissues were examined at low power under an epiﬂuor-
escence microscope. High-resolution confocal images also
were collected from the electrical recording sites as identi-
ﬁed by careful mapping. Overall, there was a clear difference
between the tissues from IL10- and vehicle-treated mice
(Figure 5A and B). Blind scoring showed that expression of
HO1 protein was signiﬁcantly higher in tissue from IL10-
compared with vehicle-treated mice (Figure 5C), and that
tissues from IL10-treated mice had more HO1-positive cells
than tissues from vehicle-treated mice. HO1-positive cells
were distributed unevenly across the tissue with patches of
positively labeled cells in some areas but not others
(Figure 5A and B). Most of the labeled cells had the
macrophage-like morphology (Figure 5D) that we previ-
ously reported for CD206-positive, F4/80-positive cells in
the gastric muscularis propria of diabetic NOD mice with
normal gastric emptying and were likely M2 macrophages.7
HO1 protein expression also was up-regulated in some
myenteric ganglia (Figure 5D) from 2 of 5 IL10-treated mice.
To test whether the HO1-positive, macrophage-like cells
were M2 macrophages, we triply labeled gastric body
muscularis propria from 2 diabetic mice that had been
treated with IL10 for 2 weeks. As shown in Figure 5E, the
majority of HO1-positive cells with macrophage-like
morphology expressed not only the panmacrophage
marker F4/80 but also the M2 macrophage marker CD206.
We examined nitric oxide synthase activity in the myenteric
plexuses of vehicle- and IL10-treated tissues by counting
NADPH-diaphorase–positive neurons. There was no differ-
ence in the number of labeled neurons (vehicle, 46 ± 11;
IL10, 42.8 ± 5.9 neurons/ﬁeld; NS, unpaired t test)
(Figure 6).
ICC networks, as identiﬁed by Kit immunoreactivity,
were signiﬁcantly different between IL10- and vehicle-
treated groups. Quantiﬁcation of the differences at the
whole-tissue level was performed by collecting high-
resolution confocal images at the location of all the elec-
trical recording sites (120 images) (Figure 7A and B), and
Figure 4. Electrical activity. Response to IL10 treatment. (A) Variability of peak amplitudes in the distal stomach (regions
7–12). Means ± SEM. *P < .05, one-way analysis of variance with Bonferroni correction; n ¼ 5. (B) Quantiﬁcation of the
interevent intervals (IEIs) for slow waves from all areas of all mice. Means ± SEM; n ¼ 5. *P < .05, unpaired t test. (C) Resting
membrane potential in the corpus (regions 1–3) and antrum (regions 7–9) of vehicle- and IL10-treated diabetic mice. Each point
represents the membrane potential for each mouse. Statistical differences were determined by repeated measures 2-way
analysis of variance with a Bonferroni post-test; N ¼ 5 mice. (D) Resting membrane potential. Note the variance in the
membrane potential across tissues was different. **P ¼ .03, F-test; means for 12 recording sites; n ¼ 5 mice. Whiskers,
medians–interquartile range. Pk, peak.
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pendent investigators on a 10-cm scale. The blinded ob-
servers reported that tissues that subsequently were
identiﬁed as vehicle-treated had clear regions where ICC
networks were depleted and, in other areas, where ICC were
present, the networks were scored as more disorganized. In
tissues subsequently identiﬁed from IL10-treated mice, the
density of ICC networks was more even across the tissue
and the networks were scored as more organized and more
evenly labeled for Kit. These scores found that ICC in IL10-
treated mice had signiﬁcantly higher ICC densities across
the whole tissue compared with vehicle-treated mice
(Figure 7C).We separately investigated whether local ICC
network changes corresponded with abnormalities in elec-
trical slow waves by selecting 2 recording locations fromeach tissue, collecting high-resolution images and deter-
mining Kit-positive ICC volume and connectivity at those
recording locations in the proximal and distal antrum from
both IL10- and vehicle-treated mice. The investigator per-
forming this work was blind to the source of the images that
were reconstructed. The volume of the Kit-positive struc-
tures in these images was not different between ICC net-
works from the 2 groups of mice in either the distal antrum
where the slow-wave changes were most prominent or in
the proximal antrum where they were less common
(Figure 7D) (n ¼ 5 mice; P > .05, unpaired t test). However,
an analysis of the count of connected structures after
morphologic opening showed that ICC networks from IL10-
treated mice were signiﬁcantly more connected than
vehicle-treated networks (Figure 7E). The algorithm used
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Figure 6. NADPH-diaphorase activity. Quantiﬁcation of
neurons in the myenteric plexus from diabetic NOD mice with
delayed gastric emptying treated with vehicle or 1 mg IL10
twice a day. Positively labeled neurons were counted from 7
high-power ﬁelds using a 20 objective from each tissue. A
minimum of 174 neurons were counted from each tissue.
There was no signiﬁcant difference in the number of positively
labeled neurons between the 2 groups (means ± SEM, t test).
462 Choi et al Cellular and Molecular Gastroenterology and Hepatology Vol. 2, No. 4for this analysis examines the impact of eroding the map
equally across the volume and examining the size and
number of the resulting fragments. In vehicle-treated mice,
the network breaks up into more objects with the same
processing compared with the samples from IL10-treated
mice (Figure 7E) (n ¼ 75 areas; P ¼ .026, unpaired t
test). These data quantify the greater organization of the ICC
networks in IL10-treated mice. To illustrate this difference,
we show examples of the largest connected Kit-positive ICC
networks in 2 ﬁelds in the distal antrum that were
segmented from a vehicle-treated and an IL10-treated
mouse (Figure 7F). These selections show a higher level of
connectivity of the ICC networks in the IL10-treated mice.Effect on Gastric Emptying of Treatment
With a Lower Dose of IL10
We also tested a 10-fold lower dose of IL10 in a separate
cohort of diabetic NOD mice with delayed emptying. After
onset of delay, mice were treated with 100 ng IL10 twice a
day. One mouse was removed from the study because
glucose levels decreased to prediabetic levels. Gastric
emptying returned to normal values in all 4 remaining mice
(Figure 8) (T1/2 predelay, 87 ± 8; pre-IL10 treatment, 196 ±
11; and post-IL10 treatment, 110 ± 8 min; P < .05 before vs
after IL10) in a mean of 4.8 weeks, which was not aFigure 5. (See previous page). HO1 expression. Image stack
Numbers indicate regions. (C) Scores for HO1 immunoreactivi
macrophages (left) and neurons in a myenteric ganglion (mid
ganglion from an IL10-treated mouse in which HO1 was not
and CD206 immunoreactivity in the muscularis propria of a d
immunolabeling in 2 different mice.signiﬁcantly different time to respond than found for the
higher 1-mg dose of IL10.
Discussion
This study shows that treatment with IL10 for delayed
gastric emptying in diabetic mice restores gastric emptying
to normal. This effect was accompanied by reduced levels of
oxidative stress indicated by lower levels of the systemic
lipid peroxidation marker, malondialdehyde, up-regulation
of HO1 expression in the muscularis propria, higher integ-
rity of Kit-positive ICC networks, and by normalization of
electrical slow wave activity.
Mice received 0.1 or 1 mg IL10 twice a day, which is
equivalent to 5–50 mg/kg twice a day in human beings.29
Animals receiving the high dose of IL10 were not more
sick than vehicle-treated mice, even though the mice under
study had increased blood glucose levels and gastroparesis.
This is consistent with the experience with IL10 in human
beings, in whom treatment was shown to be safe and well
tolerated at doses up to 25 mg/kg, with a few complications
in subjects receiving 50–100 mg/kg.29,30
There was no consistently beneﬁcial clinical response
when IL10 was tested as a treatment for inﬂammatory
bowel disease, rheumatoid arthritis, or psoriasis,31 and in
trials studying the effectiveness of IL10 in treatment of
Crohn’s disease, 20 mg/kg resulted in increased expression
of blood markers for inﬂammation.32 The side effects
observed, and lack of response to treatment, has resulted in
withdrawal of many patients treated with IL10 for Crohn’s
disease.33 Our studies indicate that diabetic delayed gastric
emptying in mice is not the result of an adaptive immune
response but is owing to a particular, macrophage-
dependent mechanism,8 which may explain why IL10 was
effective in treating delayed emptying. Interestingly, IL10
was very effective in preventing postoperative ileus in
mice,16 also an innate response and supporting the concept
that IL10 has more promise in innate immune rather than
adaptive immune disorders. This study tested IL10 as a
treatment for delayed gastric emptying and our study was
not designed to ﬁnd out if continued treatment is necessary
to sustain the beneﬁt. Further studies are necessary to
determine the optimal dose and means of delivery of IL10 to
treat gastroparesis most effectively. One possibility includes
delivering IL10 orally using IL10-releasing lactococci, as
was shown recently in another study.34
We also showed that IL10 was effective in normalizing
disrupted slow-wave activity. Disrupted slow-wave activity
was reported previously in studies that compared the
electrical properties of the gastric muscularis propria in
NOD mice with long-standing and uncontrolled diabetes
with activity in nondiabetic mice.9 Irregular electricals of HO1 immunoreactivity in (A) vehicle and (B) IL10 mice.
ty. Means ± SEM; n ¼ 5; *P < .01, t test. (D) HO1-positive
dle) from the gastric body of IL10-treated mouse. Right: a
detected in the neurons. (E) Image stacks of F4/80, HO1,
iabetic mouse treated with IL10. Data are representative of
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Figure 8. A low dose of IL10 (100 ng) also reversed
delayed gastric emptying in diabetic NOD mice. Data are
the mean T1/2 values for gastric emptying ± SEM. P < .001,
1 way analysis of variance. P < .05 vs Db before delay (a);
P < .05 vs Db before treatment (b); and not signiﬁcantly
different vs Db before delay (c). Db, diabetic.
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diabetic gastroparesis.21–23 In diabetic rodents, other
studies have reported observations similar to those that we
found in vehicle-treated mice with delayed emptying.9,20
Both groups observed more severe changes in slow-wave
activity than we did, but the pattern of changes was the
same. Ordog et al9 reported diminished slow-wave fre-
quencies and amplitudes in cells that had electrical activity,
although a majority of cells in the distal stomach (81%)
showed no slow wave. Other investigators have reported an
absence of slow waves in 13 of 19 preparations from dia-
betic rats with irregular and small events in preparations in
which activity was detected.20 The disadvantage of these
previous studies was that they could not do what we did for
this report, in which we examined the electrical properties
and cellular pathology of the tissues from each mouse,
knowing the history of the gastric emptying status of that
mouse. All of our mice received low doses of insulin to
maintain blood glucose levels at 500–600 mg/dL, so they
were not subject to severe ketoacidosis and could be
maintained alive for longer than animals that did not receive
insulin. This insulin treatment may account for the more
modest abnormalities in slow-wave properties from our
vehicle-treated animals compared with previous reports.9,20
The intrinsic pacing of the electrical slow wave in the
stomachs of dogs, pigs, and human beings has been shown,
using multi-electrode recordings, to be driven by a region
close to the greater curvature in the proximal corpus,35–37Figure 7. (See previous page). ICC networks. Image stacks fr
Means ± SD of scores for all ﬁelds; n ¼ 5; *P < .05, t test. (D)
independent connected structures after morphologic opening in
each group. *P ¼ .026, t test. (F) Three-dimensional (3D) volum
networks in 2 ﬁelds with similar total Kit volumes. Note that most
mouse are connected into a single object.and tissue dissection studies have indicated that this likely
also is true for mouse stomach.38 This pacemaker region
corresponds to region 5 (proximal corpus) in our experi-
ments, and our observations suggest that IL10 treatment
results in better coupling of the pacemaker in the corpus to
antral ICC. The immunohistochemical data showing that the
vehicle-treated mice have disrupted ICC networks and IL10-
treated mice have more even, and better-connected, ICC
networks across the whole tissue, support inefﬁcient
coupling of the pacemaker in the corpus to other parts of
the tissue in vehicle-treated mice that continue to have
delayed gastric emptying. Alternatively, abnormal slow
waves in the distal antrum of vehicle-treated mice may
reﬂect an accumulation of electrical defects as the slow
wave propagates from the corpus to antrum through the
disrupted ICC networks. Our previous studies have reported
that Kit protein expression by immunoblotting is low in
diabetic mice with delayed gastric emptying, high in diabetic
mice with normal gastric emptying, and high in mice treated
to restore gastric emptying to normal.7,8,39 Because we
observed whole tissue changes to ICC networks but no
direct correlation between the uneven slow-wave activity
and loss of ICC at the level of the recording sites, we
conclude that the key improvement in ICC networks was
network integrity. Differences in Kit protein levels might be
owing partly to the brighter Kit immunoreactivity in the
tissues from IL10-treated mice.
The variable that was most affected by IL10 treatment
was the degree of variability in the electrical slow-wave
amplitudes. IL10 reduced peak-to-peak variability by more
than 50% (see Figure 4A for quantiﬁcation). These differ-
ences in peak-to-peak height are unusual and are predicted
to disrupt coordination and force of contractility in the
distal stomach regions where the abnormalities were most
prominent. In human beings with severe symptoms of dia-
betic gastroparesis and delayed gastric emptying, the elec-
trogastrogram recordings showed a high degree of
variability consistent with disorganized pacemaking
activity.21–23 This variability was normalized after success-
ful treatment.21 It is difﬁcult to correlate the magnitude of
the improvement in electrical activity necessary for treating
gastroparesis in human beings compared with our studies in
mice because the extracellular human electrogastrogram
and the mouse intracellular slow waves are 2 different
readouts of associated phenomena. However, the observa-
tions are congruent in that disorganization and variability in
electrical activity in the signal directly correlates with
impaired gastric emptying. Irregular slow-wave activity may
emerge in the distal stomach as a cumulative effect of ICC
defects proximal to the site of the recorded electrical defect.
The presence of a difference in the resting membraneom (A) vehicle and (B) IL10 mice. (C) Network density scores.
Network volume from recording sites in antrum. (E) Count of
reconstructed images. Data are for 75 ﬁelds from 5 mice in
e-rendered bitmap of the largest connected Kit-positive ICC
of the Kit-positive structures in the ﬁeld from the IL10-treated
July 2016 Diabetic Gastroparesis Treated With IL10 465potential from proximal to distal regions of the stomach in
IL10-treated mice also may reﬂect improved function of ICC
networks in mice with normal emptying. ICC have been
shown to regulate membrane potential and by doing so to
act as a rheostat, setting the local efﬁciency of excitation-
contractility coupling.28
Treatment with IL10 resulted in increased HO1 expres-
sion in macrophage-like cells and changes to ICC networks.
It is likely that these macrophage-like cells are M2, CD206-
positive macrophages, but we cannot be certain because we
did not directly determine the CD206 or F4/80 expression
of the HO1-positive cells in the diabetic mice with delayed
gastric emptying that were treated successfully with IL10.
The likelihood that the macrophage-like cells are M2,
CD206-positive macrophages is based on the ﬁndings that
HO1 expression was identiﬁed in CD206-positive, F4/80-
positive macrophages but not other cell types in diabetic
mice with baseline normal gastric emptying that were
treated with IL10. Furthermore, we have not previously
seen HO1 expression in CD206-negative, gastric muscularis
propria macrophages, and HO1 expression is very low in
gastric muscularis propria in nondiabetic mice or diabetic
mice with delayed gastric emptying.7,8 The mechanism for
the response to IL10 may be owing to intrinsic cytopro-
tective properties of M2-macrophages40 or owing to
suppression of proinﬂammatory M1 macrophages.19 Up-
regulation of CO production owing to increased expression
of HO1 also may be key because we showed that CO alone is
sufﬁcient to normalize gastric emptying,39 and multiple
studies have shown HO1 activation in cytoprotective re-
sponses to IL10.17,41 The impact of changing macrophage
numbers and phenotype on gastric emptying also may be
mediated by other factors that have not yet been identiﬁed.
Our results also show that IL10 induces HO1 in myenteric
ganglia in some mice, which might be a speciﬁc response in
some diabetic NOD mice to IL10. Changes to MDA values
may be a consequence or a mediator of the effect of IL10.
We did not power our study to determine how IL10 affects
MDA values. MDA values in diabetic mice with delayed
gastric emptying were increased and highly variable, as
previously observed.7 We randomly assigned the 10 mice
with diabetes and delayed gastric emptying to treatment
with IL10 or vehicle. By chance, the mice receiving IL10 had
the highest MDA values, however, they still responded with
normalization of gastric emptying, despite being sicker than
the mice receiving vehicle, which did not reverse the delay
in gastric emptying and did not achieve normal MDA values.
However, given that the study was not powered to distin-
guish MDA levels between the groups assigned to vehicle
and IL10, we cannot assume a trend because the mice came
from a population of animals that was assigned blindly
without respect to MDA levels.
We did not observe a restoration of NOS activity as
previously reported when we treated delayed gastric
emptying in diabetic NOD mice using hemin or CO.7,39 This
was unexpected and requires further conﬁrmation.
The most parsimonious explanation for the cellular
response to IL10 is that IL10 induces several molecular
pathways that are beneﬁcial to gastric function, includingreduced oxidative stress, suppression of proinﬂammatory
cytokines, and activation of cellular repair. In these re-
spects, IL10 may have an advantage over inducing HO1
with hemin or administering CO because, for example,
suppression of M1-macrophages is a direct effect of IL1042
and activation of monocytes by IL10 is not dependent
on HO1 activity.43 The mechanisms for repair to ICC net-
works also were likely to be owing to an interaction of
several processes including reduced oxidative stress,
which lowers the levels of toxic products of lipid peroxi-
dation, as well as activation of proliferative and anti–cell
death pathways by CO.14
In conclusion, these studies suggest that IL10 is a
promising therapy for diabetic gastroparesis in human
beings because the response to treatment in diabetic NOD
mice affects 2 well-deﬁned characteristics of human diabetic
gastroparesis. Those features are irregular electrical rhyth-
micity21–23 and a correlation between damage to ICC and
delayed emptying.5 There is also reason to propose that
modulating macrophage phenotype using IL10 will be
effective in human beings because the number of CD206-
positive macrophages also correlates with the number of
ICC in human beings with diabetic gastroparesis.12References
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